Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 38Melanoma 36Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 10Pancreatic Neoplasms 5Neoplasm Metastasis 4Glioma 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Leukemia, Myeloid, Acute 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colonic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFR-mutant Non-small Cell Lung Cancer × trametinib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡